MentionFox
Home › Executive changes › Harvard Bioscience Inc
Leadership changes · HBIO · SEC Form 8-K, Item 5.02

Leadership changes at Harvard Bioscience Inc (2026)

Before you join, sell to or invest in Harvard Bioscience Inc

MentionFox check on Harvard Bioscience Inc: only 2 sources on file so far (checked 14 November 2026). Run a full check before you rely on it. mentionfox.com/c/executive-changes/harvard-bioscience

  • Note: Layoff plan disclosed Jan 2026 (filing)

Check Harvard Bioscience Inc before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Harvard Bioscience Inc?

Who joined and who left Harvard Bioscience Inc (HBIO)? 1 appointment reported on 2026-03-10, each cited to the company's own filing.

Mark Frost was named Chief Financial Officer of Harvard Bioscience Inc, effective March 6, 2026. As of November 14, 2026, Harvard Bioscience Inc has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on March 10, 2026, naming 1 appointment (Form 8-K, March 10, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

Leviticus Partners LP also filed stake reports on 6 other companies ↓

Sell to companies like Harvard Bioscience Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Changes1
In (appointed)1
Latest filing2026-03-10

Harvard Bioscience Inc reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-03-10. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Harvard Bioscience Inc files it.

Layoffs on record: 1 filing or notice, latest 2026-01-29 (layoff filings and notices).

Also on the record for Harvard Bioscience Inc

DateRecordFigureOur pageSource
September 22, 2026Stake report, Schedule 13G/A, by Leviticus Partners LP5.2% of the class5%+ stakesSource
May 14, 2026Stake report, Schedule 13G/A, by Leviticus Partners LP6.5% of the class5%+ stakesSource
March 23, 2026Stake report, Schedule 13D, by William Snider15.97% of the class5%+ stakesSource
February 12, 2026Stake report, Schedule 13G/A, by Leviticus Partners LP7.6% of the class5%+ stakesSource
November 3, 2025Stake report, Schedule 13G/A, by Leviticus Partners LP7.5% of the class5%+ stakesSource
August 7, 2025Stake report, Schedule 13G/A, by Leviticus Partners LP9.2% of the class5%+ stakesSource
July 17, 2025Stake report, Schedule 13G/A, by BlackRock, Inc.2.5% of the class5%+ stakesSource

Selling to them or working with them? See who runs Harvard Bioscience Inc now and the warning signs.

Free to see. No signup.

Keep reading

More on Harvard Bioscience Inc and the records around it.

Harvard Bioscience Inc elsewhere on the record

Companies that share a holder

Want the whole picture on Harvard Bioscience Inc?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Harvard Bioscience Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Harvard Bioscience Inc covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    9 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-03-10InChief Financial Officer2026-03-068-K, 2026-03-10

Who leads Harvard Bioscience Inc, as last reported?

For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.

Selling to Harvard Bioscience Inc?

New leaders reset buying decisions — get the Full Report on Harvard Bioscience Inc: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch Harvard Bioscience Inc

Hiring for a seat like this?

Find people with the same kind of experience as the Chief Financial Officer at Harvard Bioscience Inc, with the record behind each one.

Find candidates like Chief Financial Officer at Harvard Bioscience Inc

Every change, in the filing's words

Filed 2026-03-10 · 8-K

Appointed: Mark Frost, Chief Financial Officer, effective 2026-03-06

Appointment of Chief Financial Officer - Mark Frost Effective March 6, 2026, the Board of Directors of the Company appointed Mark Frost to serve as Chief Financial Officer and Treasurer of the Company.

Also stated in this filing

  • Compensatory Arrangements - John Duke On March 6, 2026, Harvard Bioscience, Inc. (the "Company") entered into an Amended and Restated Employment Agreement (the "Duke Employment Agreement") with John Duke, the Company's Chief Executive Officer.
  • The Duke Employment Agreement supersedes and replaces that certain employment agreement entered into with Mr. Duke on July 16, 2025.
  • The Duke Employment Agreement provides that Mr. Duke will receive an annual base salary of $515,000, subject to annual review beginning in 2027.
  • The term of the Duke Employment Agreement is extended until July 16, 2027, and it shall automatically be extended for two additional years following the end of the term then in effect, subject to terms in the Duke Employment Agreement.
  • In lieu of the annual bonus for fiscal year 2025, Mr. Duke will be eligible to be paid a cash bonus in the gross amount of $100,000, less applicable deductions and withholdings, based on the successful refinancing of the Company's credit facility.
  • Mr. Duke will also be eligible to receive annual cash incentive compensation of up to 80% of his base salary, payable upon meeting objectives as determined by the Board or a committee thereof, from time to time in their sole discretion.
  • In fiscal year 2026, Mr. Duke shall be eligible to receive annual equity grants, in the sole discretion of the Board or a committee thereof.

Tools for this story

Each opens in a new tab, filled in for Harvard Bioscience Inc. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/harvard-bioscience
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
Harvard Bioscience Inc names Mark Frost CFO (2026). MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/harvard-bioscience